Skip to main content
. Author manuscript; available in PMC: 2019 Feb 4.
Published in final edited form as: Cancer Chemother Pharmacol. 2017 Jun 2;80(1):165–175. doi: 10.1007/s00280-017-3346-1

Fig. 5.

Fig. 5

Simulations of 200 mg olaparib given BID on Days 1–7 either with carboplatin (blue) or without carboplatin (red). Twenty-five simulated patients in each group were given this dosing regimen; each replicated 100 times